Business Insider

Investigational, Once-weekly Insulin Icodec Showed Comparable Efficacy and Safety to Once-daily Insulin Glargine U100 in Phase 2 Trial

This material is intended for global medical media only, excl US For journalistic assessment and preparation before publication. BAGSVÆRD, Denmark, June 15, 2020 /PRNewswire/ -- Today, Novo Nordisk ...
Business Insider

Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial

BAGSVAERD, Denmark, Sept. 22, 2020 /PRNewswire/ -- Today, Novo Nordisk announced results from three phase 2 clinical trials for insulin icodec, an investigational once-weekly basal insulin analogue, ...
Nasdaq

Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3

Bagsværd, Denmark, 29 July 2022 – Novo Nordisk today announced headline results from the ONWARDS 3 and ONWARDS 4 phase 3a trials with once-weekly insulin icodec in adults with type 2 diabetes. The ...